Rosetta Genomics Reports Second Quarter 2008 Financi...(tion several othertargeted drugs for NSC...)

- Mesothelioma vs. Adenocarcinoma - Differentiating between

mesothelioma and adenocarcinoma is critical for optimal therapy, but

it is often difficult to differentiate these tumors. Currently, there

is no objective, standardized test to aid pathologists in

differentiating between the many possible tumors in the lung and

pleura. Based on a few microRNA biomarkers that were identified

applying Rosetta Genomics' technology, a test is being developed to

differentiate mesothelioma from adenocarcinoma tumors including

lung adenocarcinoma and metastases to the lung or to the pleura.

This test is expected to be filed for regulatory approval in H2 2008.

In addition, Rosetta Genomics plans to offer its own test, miRview(TM)

Meso, through its CLIA-certified lab.

- Identifying primary origin of metastases (CUP) - Rosetta

Genomics continued to advance assay development of a microRNA-based

test for cancer of unknown primary (CUP). As demonstrated in a paper

published by Rosetta Genomics and collaborators in the April issue of

Nature Biotechnology, the test is being developed to distinguish among

more than 20 possible tissues of origin, and it is expected to be

submitted for regulatory approval in H2 2008. In addition, Rosetta

Genomics plans to offer its own test, miRview(TM) Mets, through its

CLIA-certified lab.

- Additional diagnostic tests - We have advanced three new

indications into development:

- Predicting response to treatment of ovarian cancer patients -

Platinum-based cytotoxic chemotherapy in conjunction with debulking

surgery is current
'/>"/>